We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biological Standardization of Blomia Tropicalis Allergen Extract

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01597752
First Posted: May 14, 2012
Last Update Posted: November 30, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Laboratorios Leti, S.L.
  Purpose
The objective of this study is to determine the biologic activity of a Blomia tropicalis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Condition Intervention Phase
Allergy to Mites Biological: Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Biological Standardization of Blomia Tropicalis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units

Further study details as provided by Laboratorios Leti, S.L.:

Primary Outcome Measures:
  • Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase. [ Time Frame: Test sites should be inspected and recorded 15-20 min after application ]

Enrollment: 20
Study Start Date: April 2012
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1

Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)

Positive control

Negative control

Biological: Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control
Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.

Detailed Description:

This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.

Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A documented positive case history with inhalation allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) related to Blomia tropicalis.
  2. Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
  3. Subject can be male or female of any race and ethnic group.
  4. Age > 18 years and < 50 years at the study inclusion day.
  5. Positive skin prick test with a standardized commercially available preparation of Blomia tropicalis allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm and at least the size of the positive control. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
  6. A positive test for specific IgE to Blomia tropicalis(CAP-RAST ≥ 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
  7. Allergic symptoms during the season of Blomia tropicalis.
  8. Mean of the forearm major diameters of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 3 mm.

Exclusion Criteria:

  1. Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested (e.g., mites group extracts).
  2. Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1
  3. Treatment with any of the following medications: tricyclic or tetracyclic antidepressants, β-blockers or corticosteroids (> 10 mg/day of prednisone or equivalent).
  4. Pregnancy.
  5. Dermographism affecting the skin area at the test site at either study visit.
  6. Atopic dermatitis affecting the skin area at the test site at either study visit.
  7. Urticaria affecting the skin area at the test site at either study visit.
  8. Participation in another clinical trial within the last month.
  9. Subjects suffering from pathologies or conditions in which adrenalin is contraindicated (heart disease, severe hypertension,...)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01597752


Locations
Spain
Complejo Hospitalario Universitario Insular Materno-Insular
Las Palmas de Gran Canarias, Canarias, Spain, 35016
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Canarias, Spain, 35012
Sponsors and Collaborators
Laboratorios Leti, S.L.
Investigators
Study Chair: María José Gómez Laboratorios LETI, S.L.Unipersonal
  More Information

Responsible Party: Laboratorios Leti, S.L.
ClinicalTrials.gov Identifier: NCT01597752     History of Changes
Other Study ID Numbers: 107-PR-PRI-185
2011-003634-14 ( EudraCT Number )
First Submitted: May 10, 2012
First Posted: May 14, 2012
Last Update Posted: November 30, 2012
Last Verified: May 2012

Keywords provided by Laboratorios Leti, S.L.:
Immunotherapy
Skin prick test
Standardization
Blomia tropicalis